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Lead is a ubiquitous toxicant. Bone lead has been established as an important biomarker for cumulative lead exposures and has
been correlated with adverse health effects onmany systems in the body. K-shell X-ray fluorescence (KXRF) is the standardmethod
for measuring bone lead, but this approach has many difficulties that have limited the widespread use of this exposure assessment
method.With recent advancements in X-ray fluorescence (XRF) technology, we have developed a portable system that can quantify
lead in bone in vivo within 3 minutes. Our study investigated improvements to the system, four calibration methods, and system
validation for in vivomeasurements. Our main results show that the detection limit of the system is 2.9 ppm with 2mm soft tissue
thickness, the best calibration method for in vivomeasurement is background subtraction, and there is strong correlation between
KXRF and portable LXRF bone lead results. Our results indicate that the technology is ready to be used in large human population
studies to investigate adverse health effects of lead exposure. The portability of the system and fast measurement time should allow
for this technology to greatly advance the research on lead exposure and public/environmental health.
1. Introduction
Lead (Pb) exposures have decreased with the removal of Pb
from gasoline. However, Pb exposure and toxicity remains
an important public health issue. Certain populations in the
USA as well as in many developing countries still experience
high exposures. Moderate to high levels of exposure remain
commonplace globally. Recent research also shows significant
health effects at low exposure levels. In children, an inverse
association between blood Pb level and cognitive abilities is
observed at very low blood Pb concentrations, and the Pb
associated intellectual decrement was steeper at low blood Pb
levels than at higher blood Pb levels [1–3]. In adults, it has
been shown that even low Pb exposures are associated with
significant health effects among nonoccupationally exposed
populations [4–9]. Traditionally, blood Pb is used as a
biomarker to determine Pb exposures, but blood Pb has a
half-life of 30 days and therefore correlates lesswell with long-
term exposure than does bone Pb, for which the half-life is
several years to decades [10, 11]. Cd-109 induced K X-ray
fluorescence (KXRF) technology has been used to measure
Pb in bone for over two decades and has made significant
contributions to the study of associations between long-term
cumulative Pb exposure and adverse health outcomes [4, 5,
7, 12–14]. However, the system requirement of a radioactive
source, long acquisition times, and a sizeable space for the
equipment limits this research to very few groupswhopossess
this technology. In a previous study, we demonstrated the
validity of a portable XRF system that made use of Pb L
X-rays to quantify Pb in bone [15]. Improvements to this
portable system’s geometry and detector have been made,
which decrease the minimum detection limit and make the
device more compatible for use in vivo. The new system was
tested with phantoms to determine the minimum detection
limit of the device. Tests with phantom, goat bone, and
cadaver bone samples were used to determine the accuracy
of the device in determining bone Pb concentrations. Pb L
X-rays, which have relatively low energies, have greater soft
tissue attenuation for the signals and hence the correction for
this is a significant issue. To this end, new calibrationmethods
are being explored in this study to establish a more accurate
approach to quantify the Pb in bone in vivo.
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2. Materials and Methods
2.1. KXRF Bone Pb Measurement System. KXRF technology
is used in this study to validate the results found with the
portable XRF device. The setup of the device is the same as
that used in previous studies [16, 17]. The system uses four
16mm diameter high-purified germanium (HpGe) detectors
with 10mm thickness, four feedback resistance preamplifiers,
four digital signal processing systems, and a computer. A
135mCi 109Cd source is used to irradiate tibia bone or bone
equivalent samples to produce the Pb K X-rays. The bone
Pb measurements were taken for 30 minutes with the HpGe
detector and then processed with digital electronics. The
spectra were analyzed using an in-house peak fitting program
and the final Pb concentrations were calculated [17–19]. The
whole body effective dose from this system was measured to
be 0.26 𝜇Sv for adults [20].
2.2. Portable XRF Device. Two customized portable XRF
devices were used in this project (XL3t and XL3t GOLDD+,
ThermoFisher Scientific Inc., Billerica,MA).TheXL3t device
used in our previous study [15] is used in this study for
a comparison to determine how the improvements in the
device technology impact the measurements. Both devices
have an energy span up to 50 keV. Previously the device was
equipped with a thermoelectric cooled Si PIN diode with
8mm2 area and 1mm thickness. The device also has a tube
voltage of up to 50 kV, a current of up to 40 𝜇A, and various
filter combinations. The new device (XL3t-GOLDD+) has a
more compact and optimized geometry. It uses a thermo-
electric cooled silicon drift detector with a 25mm2 area and
1mm thickness. The devices were customized so that the
voltage of the X-ray tube, the current of the tube, and the filter
combinations could be selected to allow the best performance
for in vivomeasurement of Pb in bone. In our experiment, we
used ameasurement time of 3minutes. Based on our previous
study, by adjusting values for increased measurement time
and tube current, we estimated the entrance skin dose of the
systemwas 31mSv to a 1 cm2 area and thewhole body effective
dosewas 3.6 𝜇Sv [15].This can be compared to thewhole body
effective dose for a standard AP chest X-ray of about 100 𝜇Sv.
2.3. Soft Tissue and Bone Equivalent Phantoms. Soft tissue
and bone equivalent phantoms were used in this study to
determine the sensitivity of the device and to calibrate the
system. Lucite plate phantoms were used to simulate soft
tissue over bone by placing the Lucite over the flat surface
of the bone phantoms in increments of 1mm up to 5mm
of Lucite thickness. Cylindrical Pb doped phantoms made
of plaster-of-Paris were used to simulate bone with Pb
concentrations ranging from 0 to 100 ppm (0, 5, 10, 15, 20, 30,
50, 75, and 100 ppm). These measurements were made from
the flat base of the phantom. In our new calibration method
(i.e., background subtraction), the Compton scattering peak
was used to determine the background under the Pb L X-
ray peak and the attenuation of the Pb signal. Hence, MC
simulations were performed to test the differences between
plaster-of-Paris and bone and Lucite and soft tissue in terms
of Pb over Compton signal. No significant differences in
XRF spectra were found between plaster-of-Paris with Lucite
and bone with soft tissue. Thus, the phantom measurements
were used to accurately calibrate the system, correlate the
Compton peak countswith soft tissue thickness, and calculate
the detection limit of the system.
2.4. Goat Bone and Cadaver Bone Measurements. Four goat
bone samples and ten human cadaver tibia bone samples were
measuredwith the device as well.The samples had varying Pb
concentrations that were measured using KXRF. The bones
were all vacuum-sealed in plastic bags and labeled for ease
of measurements. For goat bone, measurements were made
at 0, 1, 2, 3, 4, and 5mm of Lucite and for bare cadaver
bone, measurements were made using 0, 1, 2, and 3mm of
Lucite for comparison between portable XRF devices and
KXRF. The cadaver bones measurements did not include 4
and 5mm of Lucite due to the difficulty of adjusting the
geometry in these situations.Three cadaver bone samples had
intact soft tissue over them and were measured through the
soft tissue. The cadaver and goat bone samples were taken to
give amore realistic sense of the device capabilities for in vivo
use by attempting to replicate the difficulties from increased
attenuation with LXRF energies and soft tissue thickness.
2.5. Spectrum Analysis
2.5.1. Background Subtraction. The spectrum was analyzed
using a background subtractionmethod described in detail in
our previous study [15]. In summary, the method is focused
on deriving two functions that will enable us to estimate
the Pb concentration. First, we define the relation of the
background in the Pb peak areas to Compton peak area
counts for 0 to 5mm of Lucite. Second, we define the relation
between Pb L-X ray signal and Compton peak counts for 0 to
5mm of Lucite.
The background at 0 ppm will relate to scatter events,
which will be the main contribution to background in the
spectrum. The Compton scattering peak will give a correla-
tion to the amount of scatter events in the spectrum and the
background throughout the spectrum.Thus, defining a func-
tion that will relate the Compton peak counts and the 0 ppm
background can be feasibly used to determine the back-
ground under the Pb L-X ray peaks.
The net signal will decrease with increasing Lucite thick-
ness because of an increase in attenuation of the signal as
well as distance from the bone. The Compton peak has been
shown to accurately correlate with Lucite thickness through
the increase in scatter events created by additional Lucite.
Since the attenuation and distance will increase directly with
Lucite thickness, we can correct each Pb peak by relating it
with Compton peak counts. This function can then be used
to accurately determine the signal attenuation that occurs in
each spectrum. Then, one can determine from the spectrum
the net counts coming from Pb in the sample and relate that
to a known signal concentration value to compute the final
sample concentration. In our study, as a modification to this
method for better applicability for use in vivo, we tried two
modifications in addition to the original method.
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Figure 1: Compton scattering peak counts from bone versus that
from phantomwith Lucite thicknesses increasing by 1mmwith each
point.
2.5.2. Bone Calibration. Our second method is similar to
the background subtraction method. Instead of making an
adjustment to match the phantom calibration, we made a
calibration with goat bones of known validated Pb values. For
this calibration we used four goat bones with concentrations
of 1, 13, 16, and 31 ppm of Pb at varying Lucite thicknesses
as our calibration standards for the background subtraction
method. For our 0 ppm data, we extrapolated from these
values for each Lucite thickness from the 1 ppm bone and
used our highest concentration bone at 31 ppm to replace the
100 ppm phantom in the background subtraction method.
2.5.3. Bone Adjustment. For this calibration method, we
found the difference in Compton peak between actual bone
samples and our calibration phantoms for varying Lucite
thicknesses. These peaks change both with bone versus
phantom and with varying Lucite thicknesses because of the
densities and effective𝑍 values of thematerials.This compar-
ison can be seen in Figure 1. By making this comparison we
were able to apply a fit to this change and using this fit, we can
apply the change between phantomandbone to any bone data
we take, thus correcting it for use with phantoms. After this
correction, we can apply the background subtractionmethod
used with phantoms.
2.5.4. Traditional Peak Fitting. We implemented a traditional
peak fitting method primarily for comparisons between our
novel calibration methods and the calibration methods used
in previous studies of LXRF bone Pb measurement systems
[21]. The peak fitting was carried out using MatLab. The
peaks were fitted with a Gaussian peak with an exponential
background. The fitting was performed on the Pb 𝐿
𝛼
and
𝐿
𝛽
peaks for phantoms at different Lucite thicknesses to
determine the signal associated with each concentration.
Then the same function was used to fit the 𝐿
𝛼
and 𝐿
𝛽
peaks
associated with our cadaver bone and goat bone samples and
the corresponding concentration was determined based on
the net counts in those peaks corrected for Lucite or soft
tissue attenuation. In previous studies of LXRF technology,
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Figure 2: LXRF spectrum from cadaver bone with 1.3mm soft
tissue.
it was concluded that the technology was not suitable for in
vivo bone Pb measurement due to the significant soft tissue
attenuation [21]. We included traditional peak fitting results
from our goat bone data to show the comparison to our novel
calibration methods.
3. Results
3.1. Portable XRF Spectrum. Figure 2 shows the resultant
portable XRF spectrum from a measurement of an intact
human cadaver bone with 1.3mm soft tissue. As shown in
the spectrum, the Compton scattering peak comes from the
X-ray tube silver characteristic X-rays undergoing Compton
scattering in our sample. This peak is a significant spectral
feature and can be related to the background scattering
events throughout the X-ray spectrum aswewill demonstrate
with our background subtraction calibration method in later
results. This spectrum also demonstrates the difficulty in
using traditional peak fitting methods, since with more soft
tissue, there will be more background and the peaks will
become increasingly noisier.
3.2. Detection Limit Comparison for New Portable XRF
Devices. The measurements of the Lucite covered Pb doped
phantoms were used to calculate the detection limit. The
detection limit was calculated as
DL = 2 × 𝜎
0 ppm = 2 × √
1
1/𝜎2
𝛼,0 ppm + 1/𝜎
2
𝛽,0 ppm
, (1)
where
𝜎
(𝛼,𝛽)0 ppm = 100 ppm ×
√BKG0 ppm/180 s
Gross
100 ppm − BKG0 ppm
, (2)
where BKG
0 ppm is the background count rate under the 𝐿𝛼 or
𝐿
𝛽
peak for the 0 ppm phantom and Gross
100 ppm is the total
count rate under the 𝐿
𝛼
or 𝐿
𝛽
peak for the 100 ppm phantom.
Table 1 lists the detection limit of the portable XL3t GOLDD+
system and the older portable XL3t system. This comparison
was taken at the same X-ray tube settings and filter on each
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Table 1: Detection limit for bone Pb measurement by portable XRF
devices at different soft tissue thicknesses.
Soft tissue thickness
(mm)
Detection limit XL3t
GOLDD+ (ppm)
Detection limit
XL3 (ppm)
0mm 1.2 2.0
1mm 1.8 3.5
2mm 2.9 5.9
3mm 4.6 9.6
4mm 8.0 12.8
5mm 11.0 14.7
Table 2: Phantom Pb concentrations calculated using the back-
ground subtraction method.
Standard
phantom
ppm
Lucite thickness
0mm 1mm 2mm 3mm
0 −0.38 ± 0.8 −0.1 ± 1.3 −2.22 ± 2.1 3.31 ± 3.31
5 4.83 ± 0.86 3.57 ± 1.34 9.61 ± 2.19 7.37 ± 3.37
10 10.23 ± 0.9 10.5 ± 1.39 11.23 ± 2.19 17.83 ± 3.42
15 14.9 ± 0.94 13.3 ± 1.4 20.37 ± 2.27 13.39 ± 3.41
20 19.52 ± 0.97 19.17 ± 1.46 21.25 ± 2.27 17.37 ± 3.46
30 31.32 ± 1.06 30.09 ± 1.53 30.35 ± 2.36 32.34 ± 3.56
50 47.45 ± 1.17 52.76 ± 1.7 49.43 ± 2.48 48.54 ± 3.7
75 75.56 ± 1.33 77.44 ± 1.85 74.49 ± 2.65 74.34 ± 3.82
100 96.96 ± 1.44 108.65 ± 2.02 105.26 ± 2.84 101.73 ± 4.06
device in order to demonstrate the improvements of the new
system.This data was taken for 3 minutes at the same settings
used for other measurements.
3.3. Correlation of Bone Pb Concentrations between KXRF
and Portable XRF. Measurements were made to validate the
portable XRF system against the standard KXRF systems for
in vivo bone Pb measurements. Phantoms, goat bones, and
cadaver bones with 0, 1, 2, and 3mm of Lucite were measured
by both systems, with goat bone also being measured at 4
and 5mm of Lucite thickness. Table 2 shows the measured
phantom Pb concentrations at different Lucite thicknesses.
The correlation (𝑅-squared) between the expected concen-
trations and those measured with portable XRF system
ranges from 0.991 to 0.999 for soft tissue thicknesses of 0 to
3mm, demonstrating a good agreement of Pb concentrations
determined by KXRF and portable XRF for bare and Lucite
covered phantoms.
Tables 3 and 4 demonstrate the ability of the three
calibration methods to quantify bare cadaver bone Pb values.
Table 3 shows the Pb concentration in bare cadaver bone
calculated using the three calibrationmethods. Table 4 shows
the bone Pb concentrations for cadaver bone covered with
3mm of Lucite. Without Lucite the calibration methods tend
to be fairly similar, but with the introduction of more Lucite
the bone adjustment method tends to get further from KXRF
values by overestimating background levels. Bone calibration
has a similar correlation, but with only 4 points on the
Table 3: Bone Pb concentrations for bare cadaver bone calculated
using different calibration methods.
Cadaver bone
ID KXRF
Background
subtraction
Bone
calibration
Bone
adjustment
6900 23.12 23.44 23.63 22.21
7202 22.17 19.23 19.94 18.48
6918 21.17 9.35 11.30 9.50
7131 20.77 25.59 25.53 24.34
7031 19.70 24.09 26.18 23.39
7162 18.36 17.91 18.81 17.48
7042 14.27 16.05 18.33 16.10
7002 13.54 15.29 16.48 15.15
6895 9.82 15.91 17.04 15.59
7168 3.64 1.08 3.82 −1.86
Table 4: Bone Pb concentrations for cadaver bone covered with
3mm Lucite.
Cadaver bone
ID KXRF
Background
subtraction
Bone
calibration
Bone
adjustment
6900 23.12 20.92 22.44 11.66
7202 22.17 16.72 18.53 8.14
6918 21.17 2.97 −1.35 −14.21
7131 20.77 18.10 11.76 9.61
7162 18.36 12.07 6.55 4.33
7002 13.54 10.80 13.55 3.25
6895 9.82 12.94 14.69 5.26
calibration line and the highest point at 30 ppm the actual
values tend to deviate from KXRF especially for higher Pb
concentrations. Higher concentration standards are neces-
sary to get visible signal while defining our function to correct
for the inverse square and attenuation signal degradation as
soft tissue increases. Background subtraction was the most
reliable calibration method for higher Lucite thicknesses and
lower Pb concentrations, which was determined using the
correlation values for the cadaver bone evaluated at different
Lucite thicknesses.
Figures 3(a)–3(f) show the comparison of the correlations
between goat bone Pb concentrations calculated by KXRF
and portable XRF at Lucite thicknesses of 0–5mm, with the
Pb concentrations for portable XRF being calculated using
traditional peak fitting or background subtraction. From the
correlations, one can see that traditional peak fitting does
fairly well for bare bone or at lower Lucite thicknesses,
but with higher Lucite thicknesses the correlation falls off
quickly due to the high background leading to the Pb peak
being highly distorted especially at low concentrations. The
chi-squared values for all the spectral fittings are close to
1, with the average chi-squared and standard deviation of
the chi-squared value for these fits being 1.1 ± 0.4, which
demonstrates that even for poor results the data is accurately
represented by fitted function.
The data for cadaver bones with different Lucite thick-
nesses analyzed using the background subtraction method is
Journal of Biomarkers 5
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Figure 3: (a) KXRF versus LXRF for bare goat bone. (b) KXRF versus LXRF with 1mm Lucite thickness over the goat bone. (c) KXRF versus
LXRFwith 2mmLucite thickness over the goat bone. (d) KXRF versus LXRFwith 3mmLucite thickness over the goat bone. (e) KXRF versus
LXRF with 4mm Lucite thickness over the goat bone. (f) KXRF versus LXRF with 5mm Lucite thickness over the goat bone.
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Table 5: Bone Pb concentrations for cadaver bones with different
Lucite thicknesses calculated from the background subtraction
method.
Cadaver bone Background subtraction with Lucite thickness
KXRF 0mm 1mm 2mm 3mm
6900 23.12 23.44 24.54 19.49 20.92
7202 22.17 19.23 22.02 14.56 16.72
6918 21.17 9.35 13.05 5.96 2.97
7131 20.77 25.59 20.9 21.68 18.1
7162 18.36 17.91 18.5 16.32 12.07
7002 13.54 15.29 14.48 14.54 10.8
6895 9.82 15.91 13.86 10.31 12.94
presented in Table 5. The correlations (𝑅-squared) between
the concentrations obtained from KXRF and those from the
portable XRF system range from 0.58 to 0.94 with Lucite
thicknesses of 0 to 3mm. The correlations between the Pb
concentrations obtained from KXRF and portable XRF are
worse for the cadaver bones than for the goat bones. This is
mainly due to the lack of Pb concentration variation among
the cadaver bones and geometry stability. Also, cadaver bone
6918 is an outlier (see Discussion).
To test the reliability and reproducibility of the technol-
ogy for in vivo measurement, the cadaver bones with intact
soft tissue weremeasured repeatedly. Only three such cadaver
bones were available in our lab, so there are limited data for
this test. Table 6 shows the Pb concentrations from LXRF
and KXRF for the three cadaver bones with intact soft tissue.
The bones were measured nine times using the portable
XRF device. The comparison in Table 6 demonstrates the
abilities of the device in use through actual soft tissue. Using
the Compton peak to determine soft tissue thickness, which
was shown to be comparable to an ultrasound measure-
ment in our previous paper [15], we found the intact soft
tissue thicknesses for our three cadaver bone samples to be
1.3mm for cadaver bone 7042, 4.1mm for cadaver bone 7031,
and 5.6mm for cadaver bone 7168. The higher errors for
individual measurements and higher standard deviation for
grouped measurements are associated with larger soft tissue
thicknesses, which is what we expect.
4. Discussion
This study investigated the detection limit of an improved
portable XRF system for in vivo bone Pb quantification and
validated the system using phantoms, goat bones, and human
cadaver bones. The improved system geometry and detector
size greatly enhanced the detection limit of the device and the
ability of the device to accurately determine the concentration
of Pb in bone especially at the in vivo situation.
The detection limit for the portable XRF device is
improved from the previous portable XRF device by a factor
of about 2. Through soft tissue thickness of 4mm the device
has the capability of a detection limit of 8 ppm, which is
comparable to detection limit of 6–10 ppm with KXRF bone
Pb measurement systems in most labs. It is also relevant to
Table 6: Bone Pb concentrations for three intact cadaver bones
measured by portable XRF for 9 times compared to those measured
by KXRF.
Cadaver bone ID Cadaver bone (ppm)
7042 7031 7168
KXRF 14.27 ± 1.19 19.7 ± 1.04 3.64 ± 1.07
1 14.55 ± 1.68 17.69 ± 4.74 7.07 ± 10.51
2 15.42 ± 1.69 16.4 ± 4.72 5 ± 10.44
3 14.75 ± 1.68 17.75 ± 4.66 15.8 ± 10.67
4 12.58 ± 1.66 13.63 ± 4.68 12.93 ± 10.64
5 10.98 ± 1.65 22.86 ± 4.79 12.24 ± 10.57
6 14.69 ± 1.67 18.13 ± 4.87 16.2 ± 10.71
7 13.2 ± 1.66 24.15 ± 4.95 6.89 ± 10.54
8 12.44 ± 1.64 17.67 ± 5 11.58 ± 10.75
9 12.5 ± 1.64 15.55 ± 5.01 24.25 ± 10.76
Average ± SD 13.46 ± 1.46 18.2 ± 3.34 12.44 ± 5.93
Soft tissue thickness
(mm) 1.3 4.1 5.6
point out that this was with a 3-minute measurement time
and that time could be increased by a factor of 2 or 3 to lower
the detection limit further, while maintaining a reasonable
radiation exposure. The main disadvantage of LXRF systems
is the lack of penetration of the low energy X-rays and thus
at depth, the ability of the system to determine concentration
becomes limited. With this system, it is shown that even at
depth of 4mm the portable XRFdevice nowhas the capability
of obtaining measurements in 3 minutes, which would be
equivalent to a KXRF device with a 30-minute measurement.
In studies it has been shown that tibia measurement sites
with tissue thickness of less than 4mm can be found on most
seniors and about half of the general population [15, 22]. One
of our target populations for this device is the senior people
whose mobility might be confined by their health conditions.
Another point of clarification is the fact that, with the low
penetration depth of LXRF, the KXRF and portable XRF
systems are sampling different sites of the bone. KXRF would
be sampling the whole bone and LXRF would be sampling
the superficial 0.5–1mm of the bone. It is not very clear how
Pb distributes over the layer of tibia bone and the literature on
this topic is limited. Todd et al. showed higher concentrations
of lead at 1-2mm to the surface in bone [23], while Bellis et
al. demonstrated a higher concentration of lead at a much
thinner layer [24]. While the bone Pb concentrations from
KXRF and LXRF are highly correlated in our study, further
investigation with larger amount of samples is needed on the
comparison for the absolute bone Pb concentrations from
these two methods. It is also relevant to point out that with
measurements of bone lead the goal is a correlation with
health effect, which should be reflected in both surface and
depth bone measurement sites.
ThePb concentrations found throughKXRF and portable
XRF measurements of bare bone show good correlation. In
order for our device to determine the in vivo Pb concen-
tration, our analysis methods should prove to be accurate
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with bone. Bone has different density and effective atomic
number compared to our calibration phantoms, which led to
differences in its resultant XRF spectrum. Our results with
cadaver and goat bones show that our calibration methods
adequately address these differences as the results are well
correlated with KXRF data. In comparison, the traditional
peak fitting calibration method results are shown with goat
bones, and at larger Lucite thicknesses this method is worse
than the background subtraction method. It is relevant to
point out that other studies exploring the validity of LXRF for
Pb studies used traditional peak fitting methods and showed
that the results were not reliable especially at higher soft tissue
thicknesses [21].
The background subtraction calibration method per-
formed the best in our study. The bone adjustment method
did correct the Compton peak to phantom values for a
more equal comparison, but it fails to take into account
the balance between the Compton peak, background, and
signal, and because of this, at higher Lucite thicknesses, it
exaggerates the problems seen with background subtraction.
Bone calibration should be the best calibration method in
theory, but due to the lack of standard bones with higher Pb
concentrations, the calibration line for this method tended to
produce results that were less accurate than the background
subtraction method.
The correlation of bone Pb concentrations betweenKXRF
and portable XRF is very good for phantoms and goat
bones with Lucite thickness up to 5mm, while the 𝑅-squared
degraded a little for cadaver bones. This is mainly due to
the small variation of the Pb concentration for these cadaver
bones, as well as the difficulty to adjust the geometry of
the bare bones. In measuring cadaver bones, the geometry
presented issues if not strictly monitored. We found that
the cadaver bones were prone to air gaps in the geometry,
which led to significant changes in the spectrum caused
by the increased distance without significant attenuation.
Although this effect was visible in the bare bone data, given
the geometry of in vivo measurements this effect would not
be present as the bone is covered in soft tissue, so there
will not be air gaps between the soft tissue and bone in
vivo. Attenuation by soft tissue is accounted for with our
calibration by determining the soft tissue thickness from the
Compton peak, which in turn corrects for distance, as the gap
between the detector and bone is filled with soft tissue.
Although only three intact cadaver bones were used to
test the reproducibility of the system for bone Pb quantifi-
cation and to validate the system in a real in vivo situation,
several conclusions can be drawn from these limited data.
First, this set of data confirmed the validity of the system
for in vivo measurements, especially for the measurements
with soft tissue thicknesses less than 5mm. Second, the data
confirmed that the thicknesses of the soft tissue significantly
affect the uncertainties of the resultant concentrations. The
standard deviations from the repeat measurements are lower
than the uncertainties for individual measurements, which
indicate that the uncertainties for individual measurements
may be overestimated. In addition, the detection limit of
the measurements calculated from the Pb concentration
uncertainties (DL = 2 × sigma) for cadaver bones listed
in Table 6 would be higher than those listed in Table 1 for
corresponding soft tissue thicknesses. This is because the
uncertainty calculated in Table 6 includes the error on the
gross count and net count of the signal under the Pb L X-ray
peak, while the DL calculated in Table 2 only includes error
associated with the background of a blank phantom covered
with the corresponding thicknesses of Lucite. Nonetheless,
this data set shows an excellent agreement of bone Pb
concentrations for cadaver bones at thickness of 1.3 and
4.1mm, while the agreement deteriorates at 5.6mm.
In the cadaver bone measurements, there is one bone
(cadaver bone 6918), which we considered an outlier in
our dataset. This bone came from a 100-year-old female
and presents further challenges with the LXRF device. The
spectrum from the bone had a much higher than normal
Compton peak, which we attributed to the bone appearing
more like soft tissue with respect to the spectral features.
This resulted in a more pronounced overestimation of the
background and worse signal quantification. In general the
background subtractionmethod should overcome slight vari-
ations in bone between individuals, as the Compton peak will
also relate back to the material of the bone. The relationship
we had derived between the Compton peak and the Pb signal
broke down for this particular bone.We have not isolated the
characteristic that causes this issue but plan to look into bone
density effects on the LXRF spectrum through simulation as
well as our cadaver bone samples. Although bone 6918 has
a Compton peak that is significantly different, other spectral
features show differences that may be able to be exploited to
correct the issues with the Compton peak in this spectrum.
The portable XRF system, now with a significantly lower
detection limit, has its main advantages over KXRF with
its portability, acquisition times, and ease of use. The new
system can achieve a minimum detection limit equivalent to
a KXRF measurement even through tissue thicknesses up to
5mm. The portable XRF system also has the advantage of
using an X-ray tube, which can be turned off when it is not
in use and is less complicated for radiation license than a
radioisotope source. The portable device lends itself for use
in epidemiologic studies because of its quick measurement
times and portability.The device allows for on-site Pb surveys
and risk assessments of the environment, while performing
exposure assessment of the community members.
In the future, the device can be improved by perfecting
the data analysis algorithms for Pb as well as other metals.
Monte Carlo methods could be used to accurately model the
device and the spectrum of in vivo situations. This would
help decrease the variability of measurements over different
bone densities while also accounting for the tissue thickness
over the bone. A main goal for the future of portable XRF
technology would be applying it for the detection of other
metals in vivo. The device can be used in collaboration with
metal epidemiologists and toxicologists to study exposures
and health effects of metals.
5. Conclusion
We have validated an advanced portable XRF system for in
vivo bone Pb measurement and demonstrated the validity of
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using such a system to accurately quantify Pb in bone with
soft tissue thickness up to 4-5mm.The detection limit of the
device with 4mm of soft tissue is approximately the same as
the detection limit of KXRF systems, and the novel analysis
methods provide a better correlation for Pb quantification in
bone samples. This device now has vast applicability in Pb
exposure assessment in clinical and research settings.
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